Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploratory Next Generation Sequencing to Identify Causative Variants for Bevacizumab-Induced Hypertension From Breast Cancer Study E5103 Germline DNA Samples

NCT02610413 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02610413
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02610413 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploratory Next Generation Sequencing to Identify Causative Variants for Bevacizumab-Induced Hypertension From Breast Cancer Study E5103 Germline DNA Samples
Lead sponsor
National Cancer Institute (NCI)
Phase
Observational
Overall status
Recruiting
Start date
March 25, 2014
Completion date
January 1, 2100
Enrollment
354 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast carcinoma